共 50 条
- [1] CF102 FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA: A PHASE I/II, OPEN-LABEL, DOSE-ESCALATION STUDY[J]. JOURNAL OF HEPATOLOGY, 2012, 56 : S555 - S555Stemmer, S. M.Benjaminov, O.Medalia, G.Ciuraru, N. B.Silverman, M. H.Bar-Yehuda, S.Fishman, S.Harpaz, Z.Farbstein, M.Cohen, S.Patoka, R.Singer, B.Kerns, W. D.Fishman, P.
- [2] CF102 for the Treatment of Hepatocellular Carcinoma: A Phase I/II, Open-Label, Dose-Escalation Study[J]. ONCOLOGIST, 2013, 18 (01): : 25 - 26Stemmer, Salomon M.Benjaminov, OferMedalia, GalCiuraru, Noab B.Silverman, Michael H.Bar-Yehuda, SaraFishman, SariHarpaz, ZivitFarbstein, MottiCohen, ShiraPatoka, RenanaSinger, BarakKerns, William D.Fishman, Pnina
- [3] Open-label, phase I/II dose-escalation study of ARANESP™ in patients with chronic anemia of cancer.[J]. BLOOD, 2000, 96 (11) : 154B - 155BGlaspy, JMeza, LSmith, RFleishman, AMendes, EColowick, A
- [4] Phase I/II open-label, dose-escalation trial of rituximab (Rituxan®) in patients with SLE.[J]. ARTHRITIS AND RHEUMATISM, 2000, 43 (12): : 2860 - 2860Anolik, JHCampbell, DRitchlin, CHolyst, MRosenfeld, SSanz, IYoung, FFelgar, RKunkel, LBenyunes, MGrillo-Lopéz, ARosenblatt, JLooney, RJ
- [5] Anakinra for refractory pustular psoriasis: A phase II, open-label, dose-escalation trial[J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (06) : 1380 - 1383Naik, Haley B.Pichard, Dominique C.Schwartz, Daniella M.O'Brien, MichelleMasciocchi, MatthewThompson, JulieSen, H. NidaSteinberg, Seth M.Mitchell, Sandra A.de Jesus, Adriana A.McCalmont, Timothy H.Dey, AmitRosenstein, Rachel K.Deng, ZuomingGoldbach-Mansky, RaphaelaMehta, Nehal N.Cowen, Edward W.
- [6] Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma (INTRAGO): An Open-Label, Dose-Escalation Phase I/II Trial[J]. NEUROSURGERY, 2019, 84 (01) : 41 - 49Giordano, Frank A.Brehmer, StefanieMuerle, BettinaWelzel, GritSperk, ElenaKeller, AnkeAbo-Madyan, YasserScherzinger, ElisabethClausen, SvenSchneider, FrankHerskind, CarstenGlas, MartinSeiz-Rosenhagen, MarcelGroden, ChristophHaenggi, DanielSchmiedek, PeterEmami, BahmanSouhami, LuisPetrecca, KevinWenz, Frederik
- [7] An open-label phase I/II dose escalation study of the treatment of pancreatic cancer using lithium gammalinolenate[J]. ANTICANCER RESEARCH, 1996, 16 (02) : 867 - 874Fearon, KCHFalconer, JSRoss, JACarter, DCHunter, JOReynolds, PDTuffnell, Q
- [8] Phase I/II, two-part, open-label, multiple-dose, dose-escalation study of siltuximab in patients with solid tumors[J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)Angevin, EricElez, ElenaCohen, Steven J.Van Laethem, Jean-LucOttensmeier, ChristianJoly, FlorenceRay-Coquard, IsabelleLopez-Martin, Jose A.Dirix, LucMachiels, Jean-PascalClive, SallySteven, Neil MatthewReddy, ManjulaHall, BrettPuchalski, ThomasBandekar, RajeshVan de Velde, HelgiTromp, Brenda J.Vermeulen, JessicaKurzrock, Razelle
- [9] Phase I, multicenter, open-label, dose-escalation study of sonidegib in Asian patients with advanced solid tumors[J]. CANCER SCIENCE, 2016, 107 (10) : 1477 - 1483Minami, HironobuAndo, YuichiMa, Brigette Buig YueLee, Jih-HsiangMomota, HiroyukiFujiwara, YutakaLi, LeungFukino, KoichiIto, KojiTajima, TakeshiMori, AsukaLin, Chia-Chi
- [10] An open-label phase I/II study of tamibarotene in patients with advanced hepatocellular carcinoma[J]. HEPATOLOGY INTERNATIONAL, 2014, 8 (01) : 94 - 103Kanai, FumihikoObi, ShuntaroFujiyama, ShigetoshiShiina, ShuichiroTamai, HideyukiMochizuki, HitoshiKoike, YukihiroImamura, JunYamaguchi, TakayoshiSaida, IsamuYokosuka, OsamuOmata, Masao